Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.

Abstract

Since the study was not designed to test specific safety hypotheses, results must not be overinterpreted. Nonetheless, these data emphasize the need for caution in both patient and dose selection for further studies of thrombolytic agents in stroke.